Short Circuiting
Cancer's Chaos
WHO WE ARE
Volastra is a patient-focused clinical-stage biopharmaceutical company dedicated to the discovery and development of cancer medicines that target the biology of chromosomal instability.
MORE ABOUT US
WHY CIN?
Chromosomal instability, or CIN, is a hallmark of cancer which is found in 60-80% of all tumors. It is associated with aggressive disease and poor survival.
OUR SCIENCE
IN THE CLINIC
Our two differentiated lead clinical programs each target KIF18A, a protein which plays an essential role in the successful division of cancer cells.
OUR PIPELINE
OUR RECENT PRESS RELEASES
VIEW ALL PRESS RELEASES
Volastra Therapeutics Appoints David Nicholson, Ph.D., to Board of Directors
Volastra Therapeutics, a clinical-stage cancer biotechnology company, has appointed David Nicholson, Ph.D., as an independent member of its Board of Directors.
Volastra Therapeutics Announces First Patient Dosed in Phase I/II Clinical Trial of VLS-1488, One in a Portfolio of Novel and Differentiated KIF18A Inhibitors
Volastra Therapeutics, a discovery and clinical-stage cancer biotechnology company, today announced the dosing of the first patient in a Phase I/II clinical trial evaluating VLS-1488.
Preclinical Data on Volastra Therapeutics’ Two Novel and Differentiated KIF18A Inhibitors Presented at AACR 2023
NEW YORK, April 16, 2023 – Volastra Therapeutics, a clinical-stage cancer biotechnology company focused on exploiting chromosomal instability (CIN), today […]